RxDoctor Payments Data

Francisco Castillos, MD

Hematology & Oncology · Wake Forest, NCNPI 1619978285

Payments from drug & device makers

$9,851in general payments, 2019–2025

Across 456 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Johnson & Johnson$819
  • Novartis$717
  • AstraZeneca$668
  • Incyte Corporation$630
  • Pfizer$559
  • plus $5K from 49 others

What the payments were for

  • Consulting fees$601%
  • Food & beverage$8,93691%
  • Education$8549%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,851 in reported general payments places this provider in the 50th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,154,891
Medicare patients
360
Services billed
133,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate26$462,862
ImbruvicaIbrutinib24$390,307
PromactaEltrombopag Olamine13$97,967
ProcritEpoetin Alfa24$60,777
Deferasirox12$34,491
EliquisApixaban20$20,342
XareltoRivaroxaban11$13,707
PegasysPeginterferon Alfa-2a12$13,195
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$522
Dexamethasone17$451
Chlorthalidone19$448
Albuterol Sulfate HfaAlbuterol Sulfate13$273
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril27$268
Lorazepam50$242
Ezetimibe20$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$630$462,86226 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$197$390,30724 claims
NovartisPromacta$717$97,96713 claims
Johnson & JohnsonProcrit, Xarelto$819$74,48335 claims
PfizerEliquis$559$20,34220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Wake Forest

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →